Krilogy Financial LLC trimmed its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 44.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,600 shares of the specialty pharmaceutical company’s stock after selling 1,300 shares during the period. Krilogy Financial LLC’s holdings in Jazz Pharmaceuticals PLC were worth $249,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. US Bancorp DE increased its position in shares of Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after purchasing an additional 368 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 295 shares in the last quarter. Gargoyle Investment Advisor L.L.C. purchased a new stake in Jazz Pharmaceuticals PLC in the second quarter worth approximately $206,000. Janney Montgomery Scott LLC purchased a new stake in Jazz Pharmaceuticals PLC in the second quarter worth approximately $211,000. Finally, Brighton Jones LLC purchased a new stake in Jazz Pharmaceuticals PLC in the second quarter worth approximately $213,000. Institutional investors own 88.34% of the company’s stock.
Several brokerages have issued reports on JAZZ. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $192.00 target price (up previously from $180.00) on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 9th. Morgan Stanley began coverage on Jazz Pharmaceuticals PLC in a research note on Thursday, October 5th. They issued an “equal weight” rating and a $155.00 target price for the company. Deutsche Bank AG set a $175.00 target price on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Cowen and Company reaffirmed an “outperform” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 9th. Finally, Leerink Swann upped their target price on Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, July 4th. One analyst has rated the stock with a sell rating, five have given a hold rating and eighteen have issued a buy rating to the company. Jazz Pharmaceuticals PLC currently has an average rating of “Buy” and a consensus price target of $179.79.
In related news, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $154.97, for a total value of $30,994.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Suzanne Sawochka Hooper sold 4,580 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $160.00, for a total value of $732,800.00. Following the completion of the sale, the executive vice president now directly owns 32,322 shares of the company’s stock, valued at approximately $5,171,520. The disclosure for this sale can be found here. In the last 90 days, insiders sold 9,297 shares of company stock worth $1,429,417. Company insiders own 4.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Shares Sold by Krilogy Financial LLC” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/10/12/jazz-pharmaceuticals-plc-jazz-shares-sold-by-krilogy-financial-llc.html.
Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded down 0.12% on Thursday, reaching $142.40. The company’s stock had a trading volume of 135,587 shares. The stock has a market cap of $8.55 billion, a PE ratio of 21.93 and a beta of 1.05. The firm has a 50 day moving average price of $148.70 and a 200-day moving average price of $151.57. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.13). The business had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.67 EPS. Equities research analysts expect that Jazz Pharmaceuticals PLC will post $10.88 EPS for the current year.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.